Leukemia & Lymphoma最新文献

Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者停用共价BTK抑制剂治疗后的实际结果

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-01 Epub Date: 2025-03-23 DOI: 10.1080/10428194.2025.2482132

Nitin Jain, Toby A Eyre, Katherine B Winfree, Naleen Raj Bhandari, Manoj Khanal, Tomoko Sugihara, Yongmei Chen, Paolo Abada, Krish Patel

{"title":"Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.","authors":"Nitin Jain, Toby A Eyre, Katherine B Winfree, Naleen Raj Bhandari, Manoj Khanal, Tomoko Sugihara, Yongmei Chen, Paolo Abada, Krish Patel","doi":"10.1080/10428194.2025.2482132","DOIUrl":"10.1080/10428194.2025.2482132","url":null,"abstract":"This study described real-world treatment patterns and outcomes among patients with CLL/SLL in the post-cBTKi setting. Included were patients who received at least one cBTKi and subsequent line of therapy (LOT) within the Flatiron Health nationwide electronic health record-derived de-identified database (FHD; N = 1,479) and Optum's de-identified Clinformatics® Data Mart Database (CDM; N = 1,020). Frequently observed post-cBTKi treatments in both databases included cBTKi monotherapy (23-30%), anti-CD20 mab monotherapy (∼10%), BCL2i monotherapy (∼9%), BCL2i + anti-CD20 mab (∼9%), cBTKi + BCL2i (∼3%), and cBTKi + anti-CD20 mab (5-7%). From start of immediate LOT following cBTKi discontinuation, median time-to-treatment-discontinuation ranged across databases between 6 and 9 months; median time-to-next-treatment and median overall survival ranged between 18-23 months and 36-57 months, respectively. Observed heterogeneity in treatment patterns and outcomes in two cohorts of patients with CLL/SLL suggests lack of clarity in clinical evidence for treatment choice, and there remains a need for treatment options that deliver improved outcomes in the post-cBTKi setting.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1400-1412"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. 血液肿瘤学提供者对心力衰竭高危淋巴瘤患者的淋巴瘤治疗和心脏保护策略的看法。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-01 Epub Date: 2025-04-08 DOI: 10.1080/10428194.2025.2484367

Emily Anderson, Yun Choi, Rachel J Buchsbaum, Andreas Klein, Bonnie Ky, Daniel Landsburg, Urshila Durani, Kathryn J Ruddy, Anthony F Yu, Darryl Leong, Aarti Asnani, Tomas G Neilan, Sarju Ganatra, Michelle Bloom, Ana Barac, Eric H Yang, Anita Deswal, Richard K Cheng, Matthias Weiss, Andrew M Evens, Brad Kahl, Jonathan W Friedberg, Susan K Parsons, Jenica N Upshaw

{"title":"Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure.","authors":"Emily Anderson, Yun Choi, Rachel J Buchsbaum, Andreas Klein, Bonnie Ky, Daniel Landsburg, Urshila Durani, Kathryn J Ruddy, Anthony F Yu, Darryl Leong, Aarti Asnani, Tomas G Neilan, Sarju Ganatra, Michelle Bloom, Ana Barac, Eric H Yang, Anita Deswal, Richard K Cheng, Matthias Weiss, Andrew M Evens, Brad Kahl, Jonathan W Friedberg, Susan K Parsons, Jenica N Upshaw","doi":"10.1080/10428194.2025.2484367","DOIUrl":"10.1080/10428194.2025.2484367","url":null,"abstract":"The optimal treatment of patients with diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) with preexisting cardiomyopathy is uncertain. An anonymous, electronic survey was distributed by e-mail to three US lymphoma cooperative groups, two community hospitals, and twelve academic medical systems, and distributed at one international lymphoma meeting. Fifty hematology-oncology providers caring for patients with lymphoma were included. In response to a vignette of a 67-yo with Stage III DLBCL with LVEF of 40-45%, 15 (30%) would use non-anthracycline regimens, 13 (26%) R-CHOP with liposomal doxorubicin instead of doxorubicin, 11 (22%) R-CHOP without modification and 6 (12%) R-CHOP with a continuous doxorubicin infusion. In a second vignette of a patient with HL in remission after frontline treatment with doxorubicin cumulative dose 300 mg/m2, 16 (32%) would order an echocardiogram after treatment. There was substantial variability in preferred treatment regimens with preexisting cardiomyopathy and in cardiac monitoring after anthracycline.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1437-1446"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcome. 异体干细胞移植用于mds的临床问题，选择准备方案和结果。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-01 Epub Date: 2025-03-12 DOI: 10.1080/10428194.2025.2476652

Lara Bischof, Jule Ussmann, Uwe Platzbecker, Madlen Jentzsch, Georg-Nikolaus Franke

引用次数: 0

Academic and community cancer center collaboration in acute myeloid leukemia: a road map to optimize care delivery. 急性髓性白血病的学术和社区癌症中心合作：优化护理交付的路线图。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-01 Epub Date: 2025-04-01 DOI: 10.1080/10428194.2025.2484640

Prajwal Dhakal, James O Armitage, Vijaya Raj Bhatt

{"title":"Academic and community cancer center collaboration in acute myeloid leukemia: a road map to optimize care delivery.","authors":"Prajwal Dhakal, James O Armitage, Vijaya Raj Bhatt","doi":"10.1080/10428194.2025.2484640","DOIUrl":"10.1080/10428194.2025.2484640","url":null,"abstract":"Acute myeloid leukemia (AML) poses complex management challenges and requires specialized care. Academic cancer centershave multidisciplinary teams, offer rapid and advanced diagnostics, and provideaccess to novel therapies. Community cancer centers provide care closer to home, especially for underserved and rural populations, but their resources and expertise vary. Effective collaboration between academic and community cancer centerscanimproveaccess to advanced therapies, reduce treatment disparities, and bringcare closer to home. However, barriers such as delayed referrals, resource constraints, and communication gaps complicate collaboration.Timely referral to academic centers for leukemia emergencies and serious complications is critical. Bidirectional communication, including shared electronic health records and telemedicine, is essential when patients are co-managed across centers. System-level strategies, such as referral networks, patient navigators, and transportation assistance, can further address these challenges. Developing integrated care models and standardized guidelines will enhance collaboration, enabling high-quality personalized care for individuals with AML.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1389-1399"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic impact of fever at presentation in acute myeloid leukemia: a retrospective cohort study. 急性髓系白血病发病时发热对预后的影响：一项回顾性队列研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-01 Epub Date: 2025-04-17 DOI: 10.1080/10428194.2025.2493342

Eran Levanon, Ido Peles, Eran Meyer, Etai Tarab, Idan Giterman, Yehonatan Sherf, Uri Greenbaum, Tzvika Porges

{"title":"Prognostic impact of fever at presentation in acute myeloid leukemia: a retrospective cohort study.","authors":"Eran Levanon, Ido Peles, Eran Meyer, Etai Tarab, Idan Giterman, Yehonatan Sherf, Uri Greenbaum, Tzvika Porges","doi":"10.1080/10428194.2025.2493342","DOIUrl":"10.1080/10428194.2025.2493342","url":null,"abstract":"Fever at presentation is a common clinical feature in acute myeloid leukemia (AML), yet its prognostic significance before chemotherapy initiation remains unclear. This retrospective, population-based study analyzed 198 AML patients in southern Israel from 2013 to 2023. Fever was present in 28.3% of patients and was associated with higher one-year (53.5% vs. 45.1%, p = 0.030) and five-year mortality rates (67.8% vs. 57.0%, p = 0.017). Multivariable analysis showed that fever ≥38 °C increased one-year mortality risk (OR 1.39, 95% CI 1.06-2.58, p = 0.05), rising to 1.93 for fever ≥39 °C (95% CI 1.17-2.95, p = 0.02). Median event-free survival was shorter in febrile patients (HR 1.63, 95% CI 1.14-2.35, p = 0.008), with greater association at fever ≥39 °C (HR 2.08, 95% CI 1.23-3.53, p = 0.006). Fever's prognostic association varied by age and infection status. These findings suggest that fever at presentation may serve as a clinical marker of poor prognosis in AML, warranting closer monitoring and tailored management to improve outcomes.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1498-1508"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data. 弥漫性大b细胞淋巴瘤患者的现实治疗模式、医疗资源使用和成本：对美国索赔数据的回顾性分析

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-01 Epub Date: 2025-03-31 DOI: 10.1080/10428194.2025.2482136

Mahek Garg, Ambika Satija, Yan Song, Eric M Sarpong, Benjamin Meade, Esteban Lemus-Wirtz, Katherine Gaburo, James E Signorovitch, Monika Raut, Katherine E Ryland

{"title":"Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data.","authors":"Mahek Garg, Ambika Satija, Yan Song, Eric M Sarpong, Benjamin Meade, Esteban Lemus-Wirtz, Katherine Gaburo, James E Signorovitch, Monika Raut, Katherine E Ryland","doi":"10.1080/10428194.2025.2482136","DOIUrl":"10.1080/10428194.2025.2482136","url":null,"abstract":"Treatment patterns and all-cause and diffuse large B-cell lymphoma (DLBCL)-related healthcare resource use (monthly incidence) and costs (per patient per month [PPPM]) were estimated among patients with incident DLBCL in US Optum's de-identified Clinformatics® Data Mart Database (October 2015-December 2020). Among 3664 patients, 2279 (62%) had ≥1 line (1 L), 409 (18%) had 2 L, and 99 (4%) had 3 L treatment. Rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride, vincristine, and prednisone were most common in 1 L (75%) and 2 L (23%), although multiple regimens were used in 2 L and 3 L. With increasing lines of therapy, treatment duration decreased while hospitalization rates increased. Mean DLBCL-related hospitalization costs PPPM increased with each line (1 L: $6028; 2 L: $10,708; 3 L+: $20,483), accounting for increasing proportions of total all-cause costs (1 L: 30%; 2 L: 38%; 3 L+: 56%). Thus, DLBCL poses a substantial economic burden with fewer therapeutic alternatives, especially during later lines, highlighting the need for more effective treatment options.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1447-1456"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study. polatuzumab vedotin联合苯达莫司汀和利妥昔单抗治疗日本复发和难治性DLBCL的真实数据：一项多中心回顾性研究

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-01 Epub Date: 2025-03-25 DOI: 10.1080/10428194.2025.2483390

Takahiro Fujino, Haruya Okamoto, Daichi Nishiyama, Hiroki Hayata, Nana Sasaki, Tsutomu Kobayashi, Chika Maekura, Saeko Kuwahara-Ota, Tomoko Takimoto-Shimomura, Kazuho Shimura, Yuka Kawaji-Kanayama, Yu Inoue, Shotaro Chinen, Reiko Isa, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Hiroto Kaneko, Mitsushige Nakao, Shinichi Fuchida, Ryoichi Takahashi, Hitoji Uchiyama, Nobuhiko Uoshima, Junya Kuroda

{"title":"Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.","authors":"Takahiro Fujino, Haruya Okamoto, Daichi Nishiyama, Hiroki Hayata, Nana Sasaki, Tsutomu Kobayashi, Chika Maekura, Saeko Kuwahara-Ota, Tomoko Takimoto-Shimomura, Kazuho Shimura, Yuka Kawaji-Kanayama, Yu Inoue, Shotaro Chinen, Reiko Isa, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Hiroto Kaneko, Mitsushige Nakao, Shinichi Fuchida, Ryoichi Takahashi, Hitoji Uchiyama, Nobuhiko Uoshima, Junya Kuroda","doi":"10.1080/10428194.2025.2483390","DOIUrl":"10.1080/10428194.2025.2483390","url":null,"abstract":"This study retrospectively aimed to assess the real-world efficacy and safety of polatuzumab vedotin with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma, analyzing 72 patients within the Kyoto Hematology Clinical Study Group. The median age was 77, with one-third of the participants over 80 and half having previously received three or more lines of treatment. The overall response rate was 73.6%, including 45.8% complete response. The median progression-free survival (PFS) was 7.6 months. Poor performance status, elevated lactate dehydrogenase, and disease progression within six months of the last treatment were associated with PFS and overall survival, but age over 80 and non-germinal center B-cell-like features were not. Lymphocytopenia (Grade 3-4, 82%) is prominent toxicity, and only 36% of patients completed six cycles, even though 60% required a dose reduction. While practical, our study emphasizes that Pola-BR necessitates careful toxicity management, particularly for elderly patients.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1425-1436"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centers. 治疗相关和新生CCUS的比较：来自两个中心的回顾性分析。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-01 Epub Date: 2025-03-13 DOI: 10.1080/10428194.2025.2478264

Jennifer Santos, Diana Abbott, Grace Bosma, Andrew Kent, Marc Schwartz, Christine M McMahon, Jonathan Gutman, Daniel A Pollyea, Maria L Amaya

引用次数: 0

Phosphorylation status and prognostic impacts of RSK2, PDPK1, and AKT in malignant lymphoma. 恶性淋巴瘤中RSK2、PDPK1和AKT的磷酸化状态及其对预后的影响

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-01 Epub Date: 2025-03-25 DOI: 10.1080/10428194.2025.2482891

Akio Onishi, Aya Miyagawa-Hayashino, Haruya Okamoto, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Eiichi Konishi, Junya Kuroda

{"title":"Phosphorylation status and prognostic impacts of RSK2, PDPK1, and AKT in malignant lymphoma.","authors":"Akio Onishi, Aya Miyagawa-Hayashino, Haruya Okamoto, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Eiichi Konishi, Junya Kuroda","doi":"10.1080/10428194.2025.2482891","DOIUrl":"10.1080/10428194.2025.2482891","url":null,"abstract":"Despite the oncogenic roles of the serine/threonine kinase PDPK1 and its key effectors, RSK2 and AKT, their activation status and prognostic significance remain unexamined in B cell lymphomas (BCLs). This study evaluated the phosphorylation states of PDPK1, the RSK2-N-terminal kinase domain (NTKD), and AKT through immunohistochemical analyses of 468 biopsied samples from patients with nine subtypes of MLs, including diffuse large B cell lymphoma (DLBCL) (n = 277) and follicular lymphoma (FL) (n = 121). PDPK1 was frequently phosphorylated in most subtypes, showing 98% in DLBCL and 76% in FL. RSK2-NTKD was phosphorylated in 100% and 69% of DLBCL and FL, respectively. AKT was phosphorylated in 68% and 53% of DLBCL and FL, respectively. Intriguingly, moderate to strong p-RSK2-NTKD expression significantly correlated with poor overall survival in DLBCL, especially in the non-GCB type, but not in FL. These emphasize the PDPK1/RSK2-NTKD pathway as a prognostic marker and a potential therapeutic target in various BCLs.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1413-1424"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma. 格非他单抗在复发的原发性中枢神经系统淋巴瘤中诱导深度和快速反应。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-01 Epub Date: 2025-04-02 DOI: 10.1080/10428194.2025.2484365

Weiya Wang, Meiyu Chen, Jin Li, Jie Liu, Ting Wang, Qian Song, Xuzhang Lu, Tao Chen, Zhuxia Jia

引用次数: 0